Janssen venture aims to revolutionize autism research
This article was originally published in Scrip
Executive Summary
Janssen R&D, a Johnson & Johnson-owned company, has launched a venture which it hopes will revolutionize drug development for autistic spectrum disorder by putting the research in the hands of the patients and their carers.